timothy sykes logo
DARE Bioscience Jumps As DARE to PLAY Launch Highlights Catalyst Path Thumbnail
ADD US ONG Google News

DARE Bioscience Jumps As DARE to PLAY Launch Highlights Catalyst Path

ELLIS HOBBS•UPDATED APR. 18, 2026, 11:06 AM ET
Reviewed by Matt Monaco Fact-checked by Bryce Tuohey

Dare Bioscience Inc. stocks have been trading up by 8.89 percent after pivotal clinical progress strengthened investor optimism.

Candlestick Chart

Weekly Update Apr 13 – Apr 17, 2026: On Saturday, April 18, 2026 Dare Bioscience Inc. stock [NASDAQ: DARE] is trending up by 8.89%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

Daré Bioscience (DARE) sits as a micro‑cap women’s health pure‑play with essentially no scale: trailing revenue is just over $1.0M and has declined more than 50% over three years, while price‑to‑sales is an extreme ~38x, implying valuation rests entirely on pipeline optionality. Profitability is deeply negative (EBIT margin ~‑1,280%) with ROA near ‑50% and ROE below ‑250%, underscoring structural cash burn. Key positives are a ~$25M cash balance, modest debt (total debt/equity ~0.9x) and recent positive free cash flow driven by equity issuance, not operations.

Technically, the stock has shifted from a tight base around $1.75–1.80 earlier in the week to a sharp breakout, printing a high of $3.10 and closing near $2.96 on strong volume, indicating aggressive speculative buying and a clear short‑term uptrend. The $2.70–2.75 zone, where the breakout day closed, is now the critical support and reference level for trading. An actionable setup is buying pullbacks toward $2.70 with a tight stop below $2.50, targeting a retest and extension above $3.10, assuming intraday volume on 5‑minute candles remains elevated and consolidations are shallow.

Fundamentally and relative to healthcare and biotech benchmarks, DARE is far riskier: revenue base is negligible, losses are larger as a percentage of sales, and funding needs are recurring. However, its differentiated women’s health pipeline, ARPA‑H backing for DARE‑HPV, and the 503B launch of DARE to PLAY and Flora Sync LF5 in 2026 provide discrete catalysts that peers lack. I view risk‑reward as skewed to the downside near term; fair‑value trading band is $1.75–$2.25 with strong resistance at $3.00–$3.25 until the company demonstrates durable commercial traction and non‑dilutive funding visibility.

Quick Financial Overview

Dare Bioscience Inc. (DARE) is trading like a classic high-beta biotech: sharp moves on news, anchored by a small revenue base and a growing pipeline. Weekly data show the stock lifting from the mid-$1.70s to just under $3.00 over a few days, with the key spike coming on a jump from about $1.79 to above $2.70 and then near $2.96. That kind of expansion in range tells traders liquidity and attention have picked up around recent updates.

Intraday, the single 5-minute bar near the highs shows DARE whipping between roughly $2.49 and $3.43 before closing around $2.95. This wide bar signals aggressive momentum trading and likely short-term exhaustion risk after the spike. For short-term traders, that $3.40 area becomes a clear reference for resistance, while the $2.50–$2.70 band is an immediate area to watch for support and potential pullbacks.

More Breaking News

On the fundamentals, Dare Bioscience Inc. reported about $1.02M in revenue and gross margin above 70%, but operating and net margins remain deeply negative, reflecting heavy R&D and overhead relative to sales. Cash of roughly $24.7M and current ratios near 1.0–1.1 show a modest liquidity buffer, helped by more than $20M in recent stock issuance and free cash flow turning slightly positive in the latest period. Still, return on assets and equity are sharply negative, and a price-to-sales near 38 and price-to-book around 14 underline how much of DARE’s valuation rests on future pipeline success rather than current earnings power.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading DARE

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”